How India Exports Levamisole to the World

As of March 2026, the FDA's Orange Book does not list any approved Abbreviated New Drug Applications (ANDAs) for levamisole, indicating a lack of generic approvals for this compound in the United States. Additionally, there are no current import alerts or detentions related to levamisole, suggesting that the FDA has not identified significant compliance issues with this product. The absence of approved ANDAs and import alerts implies that levamisole is not actively marketed or regulated as a pharmaceutical product in the U.S. market. This context is particularly relevant given the 72 active Indian exporters of levamisole, highlighting a potential gap or opportunity in the U.S. pharmaceutical landscape.

In February 2026, the European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) recommended the withdrawal of marketing authorizations for levamisole-containing medicines across the EU due to the risk of leukoencephalopathy, a serious neurological condition. This decision underscores the stringent safety evaluations conducted by EU regulatory bodies. In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) aligns with EMA decisions, suggesting a similar stance on levamisole. Compliance with EU Good Manufacturing Practice (GMP) requirements remains a prerequisite for any pharmaceutical product intended for the European market.

Levamisole is not listed in the current edition of the WHO Model List of Essential Medicines, indicating its limited recognition as a critical medicine globally. Furthermore, levamisole has not undergone the WHO Prequalification Programme, which assesses the quality, safety, and efficacy of medicinal products. Regarding pharmacopoeial standards, levamisole is included in the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), providing standardized quality benchmarks for its formulation and use.

In India, levamisole is classified under Schedule H of the Drugs and Cosmetics Act, requiring a prescription for its dispensation. The National Pharmaceutical Pricing Authority (NPPA) has not set a ceiling price for levamisole, indicating it is not under direct price control as of March 2026. For export purposes, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC) for pharmaceutical products, ensuring compliance with national and international regulatory standards.

Levamisole's primary patents have expired, leading to the availability of generic versions in various markets. This expiration has facilitated increased competition among manufacturers and exporters, particularly from India, which has emerged as a significant supplier of generic levamisole to multiple countries.

In February 2026, the EMA's PRAC recommended the withdrawal of marketing authorizations for levamisole-containing medicines in the EU due to safety concerns, specifically the risk of leukoencephalopathy. This decision has significant implications for exporters targeting the European market. In January 2026, the FDA updated its import alerts to reinforce that all unauthorized e-cigarettes may be detained without physical examination, reflecting the agency's stringent enforcement policies. While not directly related to levamisole, this action underscores the FDA's commitment to ensuring compliance with regulatory standards for all imported products. In October 2025, the FDA announced the implementation of import certification requirements for certain food products, effective October 31, 2025. Although this pertains to food items, it highlights the FDA's proactive approach to import regulation, which could extend to pharmaceuticals in the future.

These developments underscore the dynamic nature of the global pharmaceutical regulatory landscape, necessitating continuous monitoring and compliance by exporters to maintain market access.

India's pharmaceutical industry, including the production of Levamisole, heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) sourced from China. According to the U.S. Pharmacopeia, 41% of KSMs used in U.S.-approved APIs are solely sourced from China, while 16% come from India. This dependency poses a significant risk, as any disruption in China's supply chain can directly impact India's pharmaceutical manufacturing capabilities.

Recent geopolitical tensions have exacerbated these vulnerabilities. The closure of the Strait of Hormuz in March 2026, a critical maritime chokepoint, has disrupted global trade routes, including those essential for transporting raw materials to India. This blockade has led to increased shipping costs and delays, further straining the supply chain for Levamisole production. (lemonde.fr)

Our proprietary trade data indicates that the top five Indian exporters of Levamisole account for 66.2% of total exports, with LYKA BDR INTERNATIONAL LIMITED alone holding a 24.7% share. This high supplier concentration heightens the risk of supply disruptions, as issues affecting these key players can significantly impact global availability.

To mitigate such risks, the Indian government has implemented the Production Linked Incentive (PLI) scheme, aiming to boost domestic API production and reduce reliance on imports. However, the effectiveness of this initiative in diversifying the supplier base for Levamisole remains to be seen.

The recent military escalation in the Middle East, particularly the closure of the Strait of Hormuz, has severely disrupted global shipping routes. This strait is vital for the transportation of oil, liquefied natural gas, and other commodities, including pharmaceutical raw materials. The blockade has led to increased freight rates, extended transit times, and heightened insurance premiums, all of which adversely affect the pharmaceutical supply chain. (lemonde.fr)

Additionally, the Red Sea and the Suez Canal have experienced disruptions due to regional conflicts, further complicating shipping logistics. These challenges have forced shipping companies to reroute vessels around the Cape of Good Hope, adding significant time and cost to deliveries.

• Diversify Supplier Base: Encourage the development of alternative suppliers for Levamisole and its raw materials to reduce dependency on a limited number of exporters.

• Enhance Domestic Production: Strengthen initiatives like the PLI scheme to bolster domestic API manufacturing capabilities, thereby decreasing reliance on imports.

• Develop Alternative Shipping Routes: Invest in infrastructure and logistics to establish alternative trade routes that bypass high-risk areas like the Strait of Hormuz and the Red Sea.

• Increase Strategic Reserves: Build and maintain strategic reserves of critical raw materials and finished products to buffer against supply chain disruptions.

• Implement Robust Risk Management: Develop comprehensive risk management strategies that include scenario planning, supplier audits, and contingency plans to address potential supply chain disruptions.

RISK_LEVEL: HIGH